Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

ReNeuron Group plc (RENE) Ordinary Shares

Sell:93.00p Buy:95.00p 0 Change: 1.00p (1.08%)
Market closed Prices as at close on 24 September 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:93.00p
Buy:95.00p
Change: 1.00p (1.08%)
Market closed Prices as at close on 24 September 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:93.00p
Buy:95.00p
Change: 1.00p (1.08%)
Market closed Prices as at close on 24 September 2021 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ReNeuron Group plc is a United Kingdom-based cell-based therapeutics company. The Company develops allogeneic stem cell technology platforms, stem cell derived exosomes and induced pluripotent stem cells. The Company's products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP). The Company's exosomes nanomedicine platform focuses on generating early pre-clinical data in cancer. Its ReNcell Products include ReNcellVM and ReNcellCX cell lines. It is engaged in Phase II clinical trial of CTX cells for stroke disability. It is engaged in Phase I clinical trial of CTX cells for Critical Limb Ischaemia. It is engaged in Phase I clinical trial of hRPC stem cell candidate.

Contact details

Address:
Pencoed Business Park
BRIDGEND
CF35 5HY
United Kingdom
Telephone:
+44 (020) 38198400
Website:
www.reneuron.com/

Important dates

Future events
There are no future events available.
Past events
AGM 16 September 2021 16/09/21
Annual report 16 August 2021 16/08/21
Final results 08 July 2021 08/07/21
General meeting 11 December 2020 11/12/20
Interim results 24 November 2020 24/11/20

General stock information

EPIC:
RENE
ISIN:
GB00BF5G6K95
Market cap:
£53.52 million
Shares in issue:
56.94 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Olav Hellebo
    Chief Executive Officer, Executive Director
  • Catherine Isted
    Chief Financial Officer
  • Shaun Stapleton
    Vice President Regulatory Affairs and Pharmacovigilance
  • Richard Beckman
    Chief Medical Officer
  • Randolph Corteling
    Head of Research
  • Stefano Pluchino
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.